338 related articles for article (PubMed ID: 30737357)
1. Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes.
Corradetti B; Pisano S; Conlan RS; Ferrari M
J Pharmacol Exp Ther; 2019 Sep; 370(3):636-646. PubMed ID: 30737357
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology-based immunotherapies to combat cancer metastasis.
Zhao Y; Bilal M; Qindeel M; Khan MI; Dhama K; Iqbal HMN
Mol Biol Rep; 2021 Sep; 48(9):6563-6580. PubMed ID: 34424444
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy.
Li Y; Gao Y; Zhang X; Guo H; Gao H
Int J Pharm; 2020 Dec; 591():119986. PubMed ID: 33069895
[TBL] [Abstract][Full Text] [Related]
4. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology in ovarian cancer: Diagnosis and treatment.
Barani M; Bilal M; Sabir F; Rahdar A; Kyzas GZ
Life Sci; 2021 Feb; 266():118914. PubMed ID: 33340527
[TBL] [Abstract][Full Text] [Related]
6. The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.
Li Y; Ayala-Orozco C; Rauta PR; Krishnan S
Nanoscale; 2019 Oct; 11(37):17157-17178. PubMed ID: 31531445
[TBL] [Abstract][Full Text] [Related]
7. Improving the clinical impact of biomaterials in cancer immunotherapy.
Gammon JM; Dold NM; Jewell CM
Oncotarget; 2016 Mar; 7(13):15421-43. PubMed ID: 26871948
[TBL] [Abstract][Full Text] [Related]
8. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective.
Lan H; Zhang W; Jin K; Liu Y; Wang Z
Drug Deliv; 2020 Dec; 27(1):1248-1262. PubMed ID: 32865029
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
10. How Advanced are Cancer Immuno-Nanotherapeutics? A Comprehensive Review of the Literature.
Yadav D; Puranik N; Meshram A; Chavda V; Lee PC; Jin JO
Int J Nanomedicine; 2023; 18():35-48. PubMed ID: 36636642
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-based products for cancer immunotherapy.
Shams F; Golchin A; Azari A; Mohammadi Amirabad L; Zarein F; Khosravi A; Ardeshirylajimi A
Mol Biol Rep; 2022 Feb; 49(2):1389-1412. PubMed ID: 34716502
[TBL] [Abstract][Full Text] [Related]
12. Limitations and potential of immunotherapy in ovarian cancer.
Kumar S; Acharya S; Karthikeyan M; Biswas P; Kumari S
Front Immunol; 2023; 14():1292166. PubMed ID: 38264664
[TBL] [Abstract][Full Text] [Related]
13. The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer.
Gidwani B; Vyas A
Artif Cells Nanomed Biotechnol; 2015; 43(4):291-7. PubMed ID: 24245788
[TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.
Cho Y; Milane L; Amiji MM
Expert Opin Biol Ther; 2019 Jun; 19(6):547-560. PubMed ID: 30933545
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology and Glycosaminoglycans: Paving the Way Forward for Ovarian Cancer Intervention.
Hoosen Y; Pradeep P; Kumar P; du Toit LC; Choonara YE; Pillay V
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510526
[TBL] [Abstract][Full Text] [Related]
16. Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.
Shen H; Sun T; Hoang HH; Burchfield JS; Hamilton GF; Mittendorf EA; Ferrari M
Semin Immunol; 2017 Dec; 34():114-122. PubMed ID: 28947107
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
18. Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy.
G Lahori D; Varamini P
Future Oncol; 2021 Feb; 17(6):711-722. PubMed ID: 33136464
[TBL] [Abstract][Full Text] [Related]
19. Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer.
Rhoda K; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Pillay V
Expert Opin Drug Deliv; 2015 Apr; 12(4):613-34. PubMed ID: 25300775
[TBL] [Abstract][Full Text] [Related]
20. New Approaches for Immune Directed Treatment for Ovarian Cancer.
Hardwick N; Frankel PH; Cristea M
Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
